Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (apre una nuova finestra)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Fonte‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Indicizzato‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (apre una nuova finestra)

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? (apre una nuova finestra)

Banan M.

Fonte‎: Ann Hematol 2013;92(3):289-99.

Indicizzato‎: PubMed 23318979

DOI‎: 10.1007/s00277-012-1671-3

https://www.ncbi.nlm.nih.gov/pubmed/23318979 (apre una nuova finestra)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (apre una nuova finestra)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Fonte‎: Transfusion 2007;47(10):1830-6.

Indicizzato‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (apre una nuova finestra)

Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. (apre una nuova finestra)

Fucharoen S, Siritanaratkul N, Winichagoon P, Chowthaworn J, Siriboon W, Muangsup W, Chaicharoen S, Poolsup N, Chindavijak B, Pootrakul P, Piankijagum A, Schechter AN, Rodgers GP.

Fonte‎: Blood 1996;87(3):887-92.

Indicizzato‎: PubMed 8562958

https://www.ncbi.nlm.nih.gov/pubmed/8562958 (apre una nuova finestra)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (apre una nuova finestra)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Fonte‎: Iran J Blood Cancer 2009;1(4):147-50.

Indicizzato‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (apre una nuova finestra)

Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports. (apre una nuova finestra)

Karimi M, Cohan N, Pishdad P.

Fonte‎: Hematology 2015;20(1):53-7.

Indicizzato‎: PubMed 24717020

DOI‎: 10.1179/1607845414Y.0000000168

https://www.ncbi.nlm.nih.gov/pubmed/24717020 (apre una nuova finestra)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (apre una nuova finestra)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Fonte‎: Int J Hematol 2012;95(1):51-6.

Indicizzato‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (apre una nuova finestra)

Report on Patients with Non Transfusion-Dependent β-Thalassemia Major Being Treated with Hydroxyurea Attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. (apre una nuova finestra)

Kosaryan M, Karami H, Zafari M, Yaghobi N.

Fonte‎: Hemoglobin 2014;38(2):115-8.

Indicizzato‎: PubMed 24471558

DOI‎: 10.3109/03630269.2013.869229

https://www.ncbi.nlm.nih.gov/pubmed/24471558 (apre una nuova finestra)

Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. (apre una nuova finestra)

Musallam KM, Taher AT, Cappellini MD, Sankaran VG.

Fonte‎: Blood 2013;121(12):2199-212.

Indicizzato‎: PubMed 23315167

DOI‎: 10.1182/blood-2012-10-408021

https://www.ncbi.nlm.nih.gov/pubmed/23315167 (apre una nuova finestra)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (apre una nuova finestra)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Fonte‎: Sci Rep. 2022;12(1):2752.

Indicizzato‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (apre una nuova finestra)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (apre una nuova finestra)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Fonte‎: Haematologica 2004;89(10):1172-8.

Indicizzato‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (apre una nuova finestra)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (apre una nuova finestra)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Fonte‎: Arch Iran Med 2009;12(3):295-7.

Indicizzato‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (apre una nuova finestra)

Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (apre una nuova finestra)

Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D.

Fonte‎: Eur J Haematol 1996;56(5):326-8.

Indicizzato‎: PubMed 8641410

https://www.ncbi.nlm.nih.gov/pubmed/8641410 (apre una nuova finestra)

Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. (apre una nuova finestra)

Breymann C, Fibach E, Visca E, Huettner C, Huch A, Huch R.

Fonte‎: J Matern Fetal Med 1999;8(1):1-7.

Indicizzato‎: PubMed 10052837

DOI‎: 10.1002/(SICI)1520-6661(199901/02)8:1<1::AID-MFM1>3.0.CO;2-O

https://www.ncbi.nlm.nih.gov/pubmed/10052837 (apre una nuova finestra)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (apre una nuova finestra)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Fonte‎: Acta Haematol 2004;111(4):189-95.

Indicizzato‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (apre una nuova finestra)

Recombinant human erythropoietin therapy in a transfusion-dependent β-thalassemia major patient. (apre una nuova finestra)

Makis AC, Chaliasos N, Hatzimichael EC, Bourantas KL.

Fonte‎: Ann Hematol 2001;80(8):492-5.

Indicizzato‎: PubMed 11563599

https://www.ncbi.nlm.nih.gov/pubmed/11563599 (apre una nuova finestra)

Fetal globin induction--can it cure beta thalassemia? (apre una nuova finestra)

Perrine SP.

Fonte‎: Hematology Am Soc Hematol Educ Program 2005:38-44.

Indicizzato‎: PubMed 16304357

DOI‎: 10.1182/asheducation-2005.1.38

https://www.ncbi.nlm.nih.gov/pubmed/16304357 (apre una nuova finestra)